In mouse models of obesity, abatacept was shown to improve insulin resistance [28], and small case report and observational studies have suggested an insulin sensitizing effect of abatacept in patients with RA [18, 19, 29]. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.